It’s always gratifying when something you published in your journal is regarded by others as an important contribution. This report in yesterday’s New York Times discusses extensively the trial we published last year showing that an agonist of metabotropic glutamate receptors was beneficial in people with schizophrenia.

It’s a shame that the NYT didn’t identify Nature Medicine as the place in which the original paper was published, but so be it. I’m delighted to see that the findings are receiving the attention they deserve.